Avadel Pharmaceuticals to Speak at Future Investor Conferences

DUBLIN, Ireland, Aug. 28, 2024 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company dedicated to enhancing patient care through innovative medication solutions, has announced its participation in several upcoming investor conferences. Avadel's management team will be featured in fireside chats at the following events:

- The 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, at 3:45 p.m. ET.
- The Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6, at 10:00 a.m. ET.
- The H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 11, at 11:30 a.m. ET.

These sessions will be accessible through live webcasts available on Avadel’s Investor Relations website (investors.avadel.com) and archived for 90 days after each conference.

Avadel Pharmaceuticals plc is a company devoted to transforming lives by creating innovative medicines. Their strategy involves developing treatments that address significant issues faced by patients with existing medication options. Avadel’s flagship product, LUMRYZ™, has received FDA approval as the first and only once-at-bedtime oxybate designed to treat cataplexy or excessive daytime sleepiness (EDS) in adults suffering from narcolepsy.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!